Precision medicine in genetic epilepsies: break of dawn?

Abstract

INTRODUCTION:

Therapy with current antiepileptic drugs aims at reducing the likelihood of seizure occurrence rather than influencing the underlying disease process. Therefore, antiepileptic drugs have an anticonvulsant rather than antiepileptic property. Areas covered: The increasing identification of genetic causes for epilepsy over the recent years improves the understanding of the underlying epileptogenic process and allows for the possibility of directed therapeutic approaches. An ideal antiepileptic therapy consists of a drug which is able to influence the functional changes caused by a specific pathogenic variant. In this review we will describe the current precision medicine approaches in genetic epilepsies in reference to the identified genetic etiologies. References for this review were identified through searches of PubMed and the authors' own files. Expert commentary: Currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency, sodium channel blockers in patients with KCNQ2, SCN2A and SCN8A mutations as well as mTOR-inhibitors in mTORopathies. These predominantly represent already available treatments that were repurposed for use in epilepsy. The development of new therapeutic agents aiming at targets identified in genetic epilepsies will advance epilepsy treatment considerably.

• Authors: Philipp Sebastian Reif, Meng-Han Tsai, Ingo Helbig, Felix Rosenow, Karl Martin Klein
• Journal: Expert review of neurotherapeutics (Expert Rev Neurother) Vol. 17 Issue 4 Pg. 381-392 (04 2017) ISSN: 1744-8360 [Electronic] England
• PMID: 27781560 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• Anticonvulsants

Topics

• Anticonvulsants (therapeutic use)
• Diet, Ketogenic
• Epilepsy (genetics, therapy)
• Humans
• Mutation
• Precision Medicine